HAEMONETICS CORP Quarterly Deferred Income Tax Expense (Benefit) in USD from Q4 2015 to Q2 2025
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Haemonetics Corp quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q4 2015 to Q2 2025.
- Haemonetics Corp Deferred Income Tax Expense (Benefit) for the quarter ending June 28, 2025 was -$3.23M, a 16.1% increase year-over-year.
- Haemonetics Corp annual Deferred Income Tax Expense (Benefit) for 2024 was -$5.62M, a 48.3% increase from 2023.
- Haemonetics Corp annual Deferred Income Tax Expense (Benefit) for 2023 was -$10.9M, a 288% decline from 2022.
- Haemonetics Corp annual Deferred Income Tax Expense (Benefit) for 2022 was $5.78M, a 14.5% increase from 2021.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)